Whitepaper | 7/1/2021

Japan and China are outpacing Europe as Leading Biopharmaceutical Innovation Hubs

By Jeni Takasumi, Vivek Mittal, and Gary Cheng
The development and commercialization of novel biopharmaceutical products in recent years has continued to offer more safe and efficacious treatment options for patients across therapeutic areas. While a good proportion of the world’s transformative drug development and early commercial resources for novel therapies are focused in the United States, the level of drug innovation in the rest of the world has begun to shift. In the past decade, Japan and China have invested in regulatory reform and established policies to increase drug innovation within their respective countries.
Read here.